OFAL vs CHRS vs PRGO vs CATO

For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.

8% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -60.

1%, compared to -87. 7% for Coherus Oncology, Inc. (CHRS). Over 10 years, the gap is even starker: CATO returned -72. 3% versus CHRS's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Cato Corporation (CATO) is the lower-risk stock at 0.

88β versus Coherus Oncology, Inc. 's 2. 29β — meaning CHRS is approximately 159% more volatile than CATO relative to the S&P 500. On balance sheet safety, Coherus Oncology, Inc. (CHRS) carries a lower debt/equity ratio of 2% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.

8% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coherus Oncology, Inc.

(CHRS) is the more profitable company, earning 398. 4% net margin versus -353. 8% for OFA Group — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -429. 5% for CHRS. At the gross margin level — before operating expenses — OFAL leads at 43. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CHRS: 242.

0% to $6. 02.

In this comparison, CATO (18.

7% yield), PRGO (9. 8% yield) pay a dividend. OFAL, CHRS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Cato Corporation (CATO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

88), 18. 7% yield). Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CATO: -72. 3%, CHRS: -90. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OFAL (Industrials) and CHRS (Healthcare) and PRGO (Healthcare) and CATO (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OFAL is a small-cap quality compounder stock; CHRS is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock; CATO is a small-cap income-oriented stock. PRGO, CATO pay a dividend while OFAL, CHRS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.